Needham Maintains Buy Rating for Teleflex: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Teleflex TFX and lower its price target from $400.00 to $355.00.

Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share.

A move to $355.00 would account for a 22.11% increase from the current share price.

About Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (25% of 2021 sales), interventional (15%), anesthesia (14%), surgical (13%), interventional urology (12%), original-equipment manufacturing (9%), and all other (12%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.